Japan NHI price listing for Chugai’s Kadcyla delayed

14 November 2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss major Roche (ROG: SIX), says that the price listing of Kadcyla (trastuzumab emtansine) Intravenous Infusion 100mg and 160mg on the National Health Insurance (NHI) reimbursement list in November will be postponed.

Kadcyla, developed by Roche, was recently approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for HER2-positive inoperable or recurrent breast cancer (The Pharma Letter September 20, 2013), and Chugai has been preparing to have the price of Kadcyla listed in November.

Approval in the USA was granted for HER2-positive, late-stage (metastatic) breast cancer early this year (TPL February 25). Analysts estimate the drug could generate annual peak sales of $2 billion to $5 billion, assuming it is used earlier in the disease's progression and for longer periods of time.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK